Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and safety in diverse patient populations. The MUSETTE trial confirmed that the ...

The Elliot's Neurological Specialties clinic combines medical treatments to slow MS progression with holistic approaches to ...

NICE recommends natalizumab as a new treatment for adults with highly active relapsing-remitting multiple sclerosis ...

The company recently hit significant roadblocks with its BTK inhibitor, but there are plenty of fish in the sea for the drug ...

Machine learning can help predict whether people newly diagnosed with MS will experience disability worsening that occurs ...

Multiple sclerosis (MS) treatment could be on the brink of a significant breakthrough thanks to innovative research by Immunic Therapeutics. Speaking to Fierce Pharma, CEO Daniel Vitt shares insights ...

Should multiple sclerosis (MS) patients stop disease-modifying treatment (DMT) as they get older? The answer depends on several factors, noted John Corboy, MD, of the Rocky Mountain MS Center at the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. March is Multiple Sclerosis Awareness Month, a time to ...

A novel program provided evidence that addressing long-known disparities in high-efficacy multiple sclerosis (MS) treatment for minority populations is a solvable problem. The program, presented by ...

For guest writer Aranzazu Calzado, there's nothing like a wall to remind her that having something to lean on is not about ...

Many people with multiple sclerosis struggle with balance and coordination, and this study uncovers a hidden reason why.

NICE has recommended the drug, natalizumab, as an option for adults with relapsing-remitting MS (RRMS) that remains highly active after a full course of at least one disease-modifying therapy, and for ...